PubRank

B Moum

Author PubWeight™ 32.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther 2013 2.90
2 C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008 1.77
3 The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004 1.64
4 Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004 1.28
5 Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2005 1.26
6 Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2005 1.17
7 The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001 1.11
8 Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001 1.09
9 Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results. Am J Gastroenterol 2001 1.07
10 Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007 1.01
11 Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results. Scand J Gastroenterol 1998 0.95
12 Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2006 0.95
13 Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract 2006 0.95
14 The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013 0.93
15 Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997 0.93
16 Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ. Scand J Gastroenterol 2002 0.92
17 Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. Scand J Gastroenterol 2002 0.88
18 Fatal cytomegalovirus (CMV) colitis in a patient receiving low dose prednisolone therapy. Scand J Infect Dis 1991 0.88
19 Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 2007 0.88
20 Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Aliment Pharmacol Ther 2012 0.87
21 A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Am J Gastroenterol 1997 0.87
22 On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002 0.86
23 Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. J Rheumatol 2001 0.86
24 Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Scand J Gastroenterol 1998 0.82
25 Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther 2011 0.81
26 A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract 2005 0.81
27 Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. Aliment Pharmacol Ther 2014 0.79
28 Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005 0.78
29 Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. Scand J Gastroenterol 1997 0.78
30 [Argon plasma coagulation--a new method in therapeutic endoscopy]. Tidsskr Nor Laegeforen 2000 0.77
31 Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. Aliment Pharmacol Ther 2009 0.76
32 [Should every patient with ulcerative colitis/Crohn disease be vaccinated against pneumococcal infection?]. Tidsskr Nor Laegeforen 1997 0.75
33 [Erroneous dosage, overdosage and adverse effects following digoxin administration]. Tidsskr Nor Laegeforen 1984 0.75
34 [Gastrointestinal amyloidosis. Differential diagnosis or a complication of inflammatory bowel disease?]. Tidsskr Nor Laegeforen 1997 0.75
35 Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance. Am J Gastroenterol 1998 0.75
36 [Symptomatic cytomegalovirus infection in patients with acquired immunodeficiency syndrome]. Tidsskr Nor Laegeforen 1991 0.75
37 [Alternative treatment of Helicobacter pylori infections]. Tidsskr Nor Laegeforen 1994 0.75
38 Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease? Dig Dis 2017 0.75
39 [Reflux disease and 24-hour esophageal pH monitoring in children]. Tidsskr Nor Laegeforen 2000 0.75
40 [Incontinence following emergency surgery and ileoanal anastomosis in ulcerative colitis]. Tidsskr Nor Laegeforen 2001 0.75